For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
25
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      490
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluación positiva de medicamentos: julio y septiembre 2020 Translated title: Positive assessment of drugs: July and October 2020

      brief-report
      Author(s): , , ,
      Publication date (Print and electronic):
      Journal: Sanidad Militar
      Publisher: Ministerio de Defensa
      Keywords: Acalabrutinib (Calquence®), Amikacina (Arikayce Liposomal®), Avapritinib (Ayvakyt®), Belantamab Mafodotin (Blenrep®), Crizanlizumab (Adakveo®), Dapivirina (Dapivirine®), Filgotinib (Jyseleca®), Obiltoxaximab (Obiltoxaximab Sfl®), meningococcal group A, C, W and Y conjugate vaccine (Menquadfi®), Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) (Supemtek®), Acalabrutinib (Calquence®), Amikacina (Arikayce Liposomal®), Avapritinib (Ayvakyt®), Belantamab Mafodotin (Blenrep®), Crizanlizumab (Adakveo®), Dapivirina (Dapivirine®), Filgotinib (Jyseleca®), Obiltoxaximab (Obiltoxaximab Sfl®), Vacuna Conjugada De Los Grupos Meningocócicos A, C, W E Y (Menquadfi®), Vacuna Contra La Gripe Cuadrivalente Recombinante, Preparada En Cultivo Celular (Supemtek®)

      Read this article at

      SciELO
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en julio y septiembre de 2020, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.

          Translated abstract

          SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in July and October 2020, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

          Sagar Lonial, Hans C Lee, Ashraf Z Badros … (2019)
          Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.
          Article 0 comments Cited 303 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

            Jeff Sharman, Miklós Egyed, Wojciech Jurczak … (2020)
            Article 0 comments Cited 207 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

              Kenneth I Ataga, Abdullah Kutlar, Julie Kanter … (2017)
              The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease.
              Article 0 comments Cited 197 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): sm
                Title: Sanidad Militar
                Abbreviated Title: Sanid. Mil.
                Publisher: Ministerio de Defensa (Madrid, Madrid, Spain )
                ISSN (Print): 1887-8571
                Publication date (Print and electronic): December 2020
                Volume: 76
                Issue: 4
                Pages: 239-244
                Affiliations
                [2] orgnameServicio de Farmacología Clínica
                [1] orgnameServicio de Farmacia Hospitalaria
                [3] Madrid orgnameHospital Central de la Defensa Gómez Ulla orgdiv1Servicio de Farmacología Clínica España
                Article
                Publisher ID: S1887-85712020000400239 Publisher ID: S1887-8571(20)07600400239
                DOI: 10.4321/s1887-85712020000400006
                SO-VID: 40883a49-c24e-480e-8097-e5c97bac66ae
                License:

                http://creativecommons.org/licenses/by/4.0/

                History
                Date accepted : 03 December 2020
                Date received : 01 December 2020
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 29, Pages: 6
                Product

                SciELO Spain

                Categories
                Subject: Nota Técnica

                Keywords: Obiltoxaximab (Obiltoxaximab Sfl®),Filgotinib (Jyseleca®),Dapivirina (Dapivirine®),Vacuna Conjugada De Los Grupos Meningocócicos A, C, W E Y (Menquadfi®),Vacuna Contra La Gripe Cuadrivalente Recombinante, Preparada En Cultivo Celular (Supemtek®),Acalabrutinib (Calquence®),Amikacina (Arikayce Liposomal®),Avapritinib (Ayvakyt®),Belantamab Mafodotin (Blenrep®),Crizanlizumab (Adakveo®),meningococcal group A, C, W and Y conjugate vaccine (Menquadfi®),Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) (Supemtek®)
                Data availability:
                Keywords: Obiltoxaximab (Obiltoxaximab Sfl®), Filgotinib (Jyseleca®), Dapivirina (Dapivirine®), Vacuna Conjugada De Los Grupos Meningocócicos A, C, W E Y (Menquadfi®), Vacuna Contra La Gripe Cuadrivalente Recombinante, Preparada En Cultivo Celular (Supemtek®), Acalabrutinib (Calquence®), Amikacina (Arikayce Liposomal®), Avapritinib (Ayvakyt®), Belantamab Mafodotin (Blenrep®), Crizanlizumab (Adakveo®), meningococcal group A, C, W and Y conjugate vaccine (Menquadfi®), Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) (Supemtek®)

                Comments

                Comment on this article